Evidence map›Paper›PMID 35076584›Full record

ArticleNon-coding RNA2022

Direct Comparison of Chol-siRNA Polyplexes and Chol-DsiRNA Polyplexes Targeting STAT3 in a Syngeneic Murine Model of TNBC.

Zhen Ye, Mai Mohamed Abdelmoaty, Stephen M Curran, Shetty Ravi Dyavar, Devendra Kumar, Yazen Alnouti, Don W Coulter, Anthony T Podany, Rakesh K Singh, Joseph A Vetro

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Non-coding RNA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Zhen YeDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Mai Mohamed AbdelmoatyDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0001-7672-7052
Stephen M CurranDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Shetty Ravi DyavarDepartment of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Devendra KumarDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Yazen AlnoutiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Don W CoulterDepartment of Pediatrics, Division of Pediatric Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Anthony T PodanyDepartment of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Rakesh K SinghCenter for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0002-1317-3520
Joseph A VetroDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0003-2446-9797
Nebraska Medical Center · USUniversity of Nebraska Medical Center · US

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Apar Kishor Ganti · 1985 to 2026
$55.0M
Targeting CXCR2 axis in Pancreatic CancerR01CA228524 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K., SINGH, RAKESH K · 2018 to 2022
$2.0M
EP67-Based Targeted Mucosal Vaccines to Prevent Primary Infection with CMVR01AI121050 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI VETRO, JOSEPH ANTHONEY · 2016 to 2020
$1.9M
Development of Chol-DsiRNA Polyplexes to Improve the Therapy of Breast CancerR41TR001902 · NCATS · ACTORIUS PHARMACEUTICALS, LLC · PI VETRO, JOSEPH ANTHONEY · 2016 to 2016
$325k
NCATS NIH HHS R41 TR001902NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA228524NIAID NIH HHS R01 AI121050NIH HHS 1R41TR001902-01A1NIH HHS P30CA03672NIH HHS R01CA228524State of Nebraska LB 417
6 · The paper itself

Abstract

RNA interference (RNAi) molecules have tremendous potential for cancer therapy but are limited by insufficient potency after intravenous (IV) administration. We previously found that polymer complexes (polyplexes) formed between 3'-cholesterol-modified siRNA (Chol-siRNA) or DsiRNA (Chol-DsiRNA) and the cationic diblock copolymer PLL[30]-PEG[5K] greatly increase RNAi potency against stably expressed LUC mRNA in primary syngeneic murine breast tumors after daily IV dosing. Chol-DsiRNA polyplexes, however, maintain LUC mRNA suppression for ~48 h longer after the final dose than Chol-siRNA polyplexes, which suggests that they are the better candidate formulation. Here, we directly compared the activities of Chol-siRNA polyplexes and Chol-DsiRNA polyplexes in primary murine 4T1 breast tumors against STAT3, a therapeutically relevant target gene that is overexpressed in many solid tumors, including breast cancer. We found that Chol-siSTAT3 polyplexes suppressed STAT3 mRNA in 4T1 tumors with similar potency (half-maximal ED

Indexed as

Chol-DsiRNA polymer micellesChol-siRNA polymer micellesdrug deliveryDsiRNA deliveryRNAiRNAi deliverysiRNA delivery

Identifiers

PMID35076584
PMCPMC8788547
OpenAlexW4226053677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.